The medical diagnostics company posted a pretax loss of
ANGLE said it had made significant progress with the commercialisation of Parsortix during the year, and is now focused on establishing its use in clinical practice.
Parsortix is used to capture circulating tumour cells from cancer patient blood for mutational analysis, using a simple blood test to capture the cancer cells for analysis.
During the year the company sold its video game lighting company Geomerics business to
It continued to bolster its patent portfolio covering Parsortix during he year, filing new submissions which would provide further patent coverage to late 2033. Its current US patent provides cover until 2026.
ANGLE will need regulatory authorisation before Parsortix can be sold for use in the clinical market, although earlier sales can be made into the research market, it said. During the year ANGLE secured a CE mark for the use of the system as an in vitro diagnostic device in the EU.
The company made a submission to the
On Tuesday the company said it had seen a positive evaluation of its Parsortix system by the University of
Shares in Angle were trading up 0.6% at
Most Popular Stories
- Pickup Discounts Boost September Auto Sales
- Kurdish Militia Still Lack Weapons, Training
- Lexus Luxury Compact Sedan Wins Buyers
- Review: Pay by Phone or Just Keep Using Plastic?
- Ebola Victim Was Sent Home by Dallas Hospital
- N.Y. Ups Awards of State Contracts to Minorities
- Dallas Parents Fear Students Exposed to Ebola
- Group Offers Online Help for College Students
- Why the Bond Market Isn't as Safe as You Think
- Baker Hughes to Disclose Fracking Chemicals